Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Gene variation affects asthma drug treatment

13.06.2006
Researchers at the University of Dundee have discovered that a significant proportion of young asthmatics may not benefit from a commonly used asthma medicine known as salmeterol, due to a gene variation which is present in around 13% of the population.

A research team led by Dr Somnath Mukhopadhyay, Professor Brian Lipworth and Dr Colin Palmer, has found that a specific genetic variant, known as the Arg/Arg-16 variant, causes salmeterol to be ineffective.

Their research shows that while most patients on salmeterol have their asthma well controlled, those with the Arg/Arg-16 variant have almost double the number of asthma attacks compared to those with the other forms of this gene.

Future research will determine if genetic testing for the Arg/Arg 16 variant should be used in deciding routine asthma prescribing. This is a first step in the path to "personalized medicine" where genetic information will lead to the more effective use of drugs.

"It was apparent that some patients with asthma could be failing to respond to inhaled salmeterol, but we have identified a likely cause for this that is linked to this genetic status," said Dr Mukhopadhyay, of the Children’s Asthma and Allergy Research Unit at the University.

"Where this discovery takes us is towards more personalised asthma treatment, where we can identify which medicines can be used or avoided depending on an individual’s genetic profile and we can ensure the best possible treatment."

The Arg/Arg-16 variant genetic status is reasonably common and it is present in around 13% of young people with asthma in Tayside. The Dundee team studied 546 children and adolescents with asthma in Tayside.

The findings follow studies in America where the US Food and Drug Administration, the principal food and drug regulatory organisation in the United States, has previously warned in November 2005 that salmeterol was not effective in certain individuals, especially African Americans, although the genetic status of these individuals was not studied.

Salmeterol is part of a group of drugs known as beta-agonists, and is widely prescribed within the National Health Service to patients with asthma who fail to respond well to inhaled steroids.

There are 5.2 million people in the UK currently receiving various forms of asthma treatment, and an estimated 675,000 within this population carry the Arg/Arg-16 gene variation and therefore may not benefit from salmeterol treatment.

There are other drugs that can be used as alternative treatments in these individuals.

Although genetic testing is not performed through the NHS, it is important to note that the patients who are put on salmeterol should monitor if the medicine is working or not. If asthma is still poorly controlled on salmeterol, then alternatives, rather than additional treatments, may be more useful.

The results are published today by the leading chest medical journal Thorax, published by the British Thoracic Society and the BMJ Publishing Group.

Roddy Isles | alfa
Further information:
http://www.dundee.ac.uk

More articles from Health and Medicine:

nachricht Biofilm discovery suggests new way to prevent dangerous infections
23.05.2017 | University of Texas at Austin

nachricht Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Strathclyde-led research develops world's highest gain high-power laser amplifier

The world's highest gain high power laser amplifier - by many orders of magnitude - has been developed in research led at the University of Strathclyde.

The researchers demonstrated the feasibility of using plasma to amplify short laser pulses of picojoule-level energy up to 100 millijoules, which is a 'gain'...

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

New insights into the ancestors of all complex life

29.05.2017 | Earth Sciences

New photocatalyst speeds up the conversion of carbon dioxide into chemical resources

29.05.2017 | Life Sciences

NASA's SDO sees partial eclipse in space

29.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>